Published in Breast Cancer Res Treat on February 01, 2007
Male breast carcinoma: increased awareness needed. Breast Cancer Res (2011) 1.40
Male breast cancer: a review. Ecancermedicalscience (2009) 0.87
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. Sci Rep (2016) 0.75
Clinicopathologic characteristics and survival of male breast cancer. Int J Clin Oncol (2013) 0.75
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Towards using administrative databases to measure population-based indicators of quality of end-of-life care: testing the methodology. Palliat Med (2006) 1.60
Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04. CMAJ (2007) 1.42
Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999-2000. CMAJ (2004) 1.36
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev (2012) 1.21
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer (2008) 1.19
Interfaces across the cancer continuum offer opportunities to improve the process of care. J Natl Cancer Inst Monogr (2010) 1.18
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat (2008) 1.17
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer (2005) 1.10
Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev (2008) 1.04
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat (2012) 1.02
The coordination of primary and oncology specialty care at the end of life. J Natl Cancer Inst Monogr (2010) 1.01
Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol (2008) 0.98
Relationship of time since childbirth and other pregnancy factors to premenopausal breast cancer prognosis. Obstet Gynecol (2008) 0.97
Waiting times in early-stage non-small cell lung cancer (NSCLC). J Thorac Oncol (2008) 0.97
Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors. Arch Pathol Lab Med (2011) 0.96
Application of the probabilistic approach to reporting breast fine needle aspiration in males. Acta Cytol (2008) 0.96
Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy. Clin Breast Cancer (2011) 0.95
Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. Clin Breast Cancer (2011) 0.94
A team approach to improving colorectal cancer services using administrative health data. Health Res Policy Syst (2012) 0.92
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat (2014) 0.92
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer (2012) 0.92
Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat (2007) 0.91
Trends in the incidence of oral cancer in Nova Scotia from 1983 to 1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2003) 0.87
Improving nodal harvest in colorectal cancer: so what? Ann Surg Oncol (2011) 0.86
The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health (2011) 0.85
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol (2009) 0.85
Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Ann Surg Oncol (2014) 0.85
The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat (2007) 0.84
End-of-life care for nursing home residents dying from cancer in Nova Scotia, Canada, 2000-2003. Support Care Cancer (2007) 0.84
Population-based longitudinal study of follow-up care for patients with colorectal cancer in Nova Scotia. J Oncol Pract (2012) 0.84
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res (2002) 0.83
Survivin and COX-2 expression in male breast carcinoma. Breast (2009) 0.82
Flat epithelial atypia on breast needle core biopsy: a retrospective study with clinical-pathological correlation. Breast J (2010) 0.82
Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins. J Surg Oncol (2005) 0.82
The decision-making experience among women diagnosed with stage I and II breast cancer. Breast Cancer Res Treat (2006) 0.81
A population-based case-control study of occupational exposure to acids and the risk of lung cancer: evidence for specificity of association. Int J Occup Environ Health (2011) 0.81
Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer? Expert Rev Pharmacoecon Outcomes Res (2013) 0.81
Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact. Breast J (2014) 0.81
Quantifying limitations in chemotherapy data in administrative health databases: implications for measuring the quality of colorectal cancer care. Healthc Policy (2011) 0.81
How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study. Implement Sci (2012) 0.79
Ten years of breast screening in the Nova Scotia Breast Screening Program, 1991-2001. experience: use of an adaptable stereotactic device in the diagnosis of screening-detected abnormalities. Can Assoc Radiol J (2005) 0.79
Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors. Neuroendocrinology (2011) 0.79
CytoLyt® fixation and decalcification pretreatments alter antigenicity in normal tissues compared with standard formalin fixation. Appl Immunohistochem Mol Morphol (2015) 0.79
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer. Oncologist (2013) 0.78
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations. Clin Med Insights Oncol (2012) 0.78
Compression garments versus compression bandaging in decongestive lymphatic therapy for breast cancer-related lymphedema: a randomized controlled trial. Support Care Cancer (2011) 0.78
Gendered and cultured relations: exploring African Nova Scotians' perceptions and experiences of breast and prostate cancer. Res Theory Nurs Pract (2005) 0.78
Fine-needle aspiration cytology of mammary fibroadenoma: a comparison of ThinPrep® and cytospin preparations. Diagn Cytopathol (2011) 0.77
Premature mortality due to social and material deprivation in Nova Scotia, Canada. Int J Equity Health (2014) 0.77
Hereditary breast cancer: shared communication and care. J Clin Oncol (2003) 0.75
Accrual strategies for cancer genetics research: blurred boundaries. J Clin Oncol (2010) 0.75
Exercise and cancer: no pain, some gain? J Clin Oncol (2003) 0.75
Isolated metastasis to the cerebellopontine angle secondary to breast cancer. Can J Surg (2009) 0.75
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment. Support Care Cancer (2014) 0.75
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Res Treat (2009) 0.75
Examining stage IIB survival in a population-based cohort of patients with colorectal cancer. Cancer (2012) 0.75